Semaglutide weight-loss drug shows promising results for obese teens.
TL;DR Summary
A new study found that nearly half of obese adolescents who were administered semaglutide, a weight-loss drug, were no longer considered clinically obese by the end of a 16-month trial. The drug, which goes by the brand names of Ozempic and Wegovy, was found to be "highly effective" in reducing body mass index among teens. The study adds to existing research that a weekly self-administered injection of Wegovy or Ozempic can be effective in reducing body weight and lowering some of the health risks associated with obesity.
- Weight loss drug reverses obesity for nearly half of teens in study The Washington Post
- Almost half of children on the weight-loss drug semaglutide are no longer clinically obese, landmark study finds Yahoo! Voices
- Obese teens must be put on weight loss jabs for life, experts say... The US Sun
- Quarter of Wegovy-Treated Teens With Obesity Return to Normal Weight Medpage Today
- Teenagers with obesity should be offered weight loss drug, say experts The Independent
Reading Insights
Total Reads
0
Unique Readers
11
Time Saved
3 min
vs 4 min read
Condensed
89%
770 → 87 words
Want the full story? Read the original article
Read on The Washington Post